(0.00%) 5 187.67 points
(0.44%) 39 056 points
(-0.18%) 16 303 points
(0.37%) $79.28
(-0.27%) $2.18
(-0.28%) $2 315.70
(-0.22%) $27.54
(-0.01%) $984.50
(0.07%) $0.931
(0.14%) $10.91
(0.05%) $0.801
(0.01%) $91.74
4 days till quarter result
(bmo 2024-05-13)
Expected move: +/- 21.05%
0.66% $ 7.59
@ $8.91
Wydano: 14 vas. 2024 @ 21:26
Zwrot: -14.81%
Poprzedni sygnał: vas. 13 - 22:22
Poprzedni sygnał:
Zwrot: -1.22 %
Live Chart Being Loaded With Signals
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States...
Stats | |
---|---|
Dzisiejszy wolumen | 216 415 |
Średni wolumen | 618 170 |
Kapitalizacja rynkowa | 471.75M |
EPS | $0 ( 2024-02-27 ) |
Następna data zysków | ( $-0.440 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.77 |
ATR14 | $0.0130 (0.17%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-18 | Horn Patrick Taylor | Buy | 400 000 | Stock Option (right to buy) |
2024-03-18 | Horn Patrick Taylor | Sell | 0 | No securities are beneficially owned |
2024-03-08 | Tourangeau Greg | Sell | 4 884 | Common Stock |
2024-03-04 | Sapir Alex | Buy | 43 360 | Common Stock |
2024-01-26 | Tourangeau Greg | Buy | 83 820 | Stock Option (right to buy) |
INSIDER POWER |
---|
20.69 |
Last 98 transactions |
Buy: 8 691 029 | Sell: 9 119 346 |
Wolumen Korelacja
Fulcrum Therapeutics Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
ABST | 0.942 |
CSX | 0.939 |
MULN | 0.929 |
VNET | 0.928 |
ALLO | 0.927 |
RLMD | 0.92 |
CNDT | 0.919 |
IDLB | 0.918 |
PTH | 0.917 |
EGAN | 0.917 |
10 Najbardziej negatywne korelacje | |
---|---|
RMRM | -0.949 |
RDUS | -0.927 |
XOG | -0.9 |
TYHT | -0.895 |
EPZM | -0.881 |
RTPY | -0.876 |
SVOK | -0.874 |
OPCH | -0.871 |
SYKE | -0.868 |
HSTM | -0.864 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Fulcrum Therapeutics Inc Korelacja - Waluta/Towar
Fulcrum Therapeutics Inc Finanse
Annual | 2023 |
Przychody: | $2.81M |
Zysk brutto: | $633 000 (22.57 %) |
EPS: | $-1.590 |
FY | 2023 |
Przychody: | $2.81M |
Zysk brutto: | $633 000 (22.57 %) |
EPS: | $-1.590 |
FY | 2022 |
Przychody: | $6.34M |
Zysk brutto: | $3.93M (61.94 %) |
EPS: | $-2.35 |
FY | 2021 |
Przychody: | $19.16M |
Zysk brutto: | $19.16M (100.00 %) |
EPS: | $-2.29 |
Financial Reports:
No articles found.
Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej